You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/68433
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTávora de Albuquerque Silva, Antonio-
dc.contributor.authorChin, Chung Man-
dc.contributor.authorCastro, Lúcia Fioravanti-
dc.contributor.authorCarvalho Güido, Rafael Victorio-
dc.contributor.authorFerreira, Elizabeth Igne-
dc.date.accessioned2014-05-27T11:21:38Z-
dc.date.accessioned2016-10-25T18:21:10Z-
dc.date.available2014-05-27T11:21:38Z-
dc.date.available2016-10-25T18:21:10Z-
dc.date.issued2005-10-01-
dc.identifierhttp://dx.doi.org/10.2174/138955705774329528-
dc.identifier.citationMini-Reviews in Medicinal Chemistry, v. 5, n. 10, p. 893-914, 2005.-
dc.identifier.issn1389-5575-
dc.identifier.urihttp://hdl.handle.net/11449/68433-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/68433-
dc.description.abstractThe background of prodrug design is presented herein as the basis for introducing new and advanced latent systems, taking into account mainly the versatility of polymers and other macromolecules as carriers. PDEPT (Polymer-Directed Enzyme Prodrug Therapy); PELT (Polymer-Enzyme Liposome Therapy); CDS (Chemical Delivery System); ADEPT(Antibody-Directed Enzyme Prodrug Therapy); GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Virus-Directed Enzyme Prodrug Therapy); ODDS (Osteotropic Drug Delivery System) and LEAPT (Lectin-directed enzyme-activated prodrug therapy) are briefly described and some examples are given. © 2005 Bentham Science Publishers Ltd.en
dc.format.extent893-914-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectLatent advanced systems-
dc.subjectMacromolecules carriers-
dc.subjectProdrug design-
dc.subjectSelective delivery systems-
dc.subjectaminosalicylic acid-
dc.subjectampicillin-
dc.subjectantiinflammatory agent-
dc.subjectantileishmanial agent-
dc.subjectantimalarial agent-
dc.subjectantineoplastic agent-
dc.subjectbisphosphonic acid derivative-
dc.subjectcytochrome P450-
dc.subjectdiclofenac-
dc.subjectdoxorubicin-
dc.subjectflucytosine-
dc.subjectibuprofen-
dc.subjectirinotecan-
dc.subjectisoniazid-
dc.subjectketoprofen-
dc.subjectmevinolin-
dc.subjectmitomycin-
dc.subjectnitrofural-
dc.subjectpaclitaxel derivative-
dc.subjectphotosensitizing agent-
dc.subjectprodrug-
dc.subjectsalazosulfapyridine-
dc.subjecttacrolimus-
dc.subjecttestosterone derivative-
dc.subjecttiaprofenic acid-
dc.subjecttolmetin-
dc.subjecttrigonelline-
dc.subjecttryptamine derivative-
dc.subjectunindexed drug-
dc.subjectantibody directed enzyme prodrug therapy-
dc.subjectbactericidal activity-
dc.subjectbinding affinity-
dc.subjectblood brain barrier-
dc.subjectChagas disease-
dc.subjectdiarrhea-
dc.subjectdrug absorption-
dc.subjectdrug activation-
dc.subjectdrug design-
dc.subjectdrug distribution-
dc.subjectdrug identification-
dc.subjectdrug receptor binding-
dc.subjectdrug screening-
dc.subjectdrug selectivity-
dc.subjectdrug stability-
dc.subjectdrug structure-
dc.subjectdrug synthesis-
dc.subjectdrug targeting-
dc.subjectdrug transformation-
dc.subjectgastrointestinal toxicity-
dc.subjectgene expression-
dc.subjecthuman-
dc.subjecthypercholesterolemia-
dc.subjectin vivo study-
dc.subjectmacromolecule-
dc.subjectmalaria-
dc.subjectminimum inhibitory concentration-
dc.subjectnephrotoxicity-
dc.subjectorganoleptic property-
dc.subjectosteoporosis-
dc.subjectreview-
dc.subjectrheumatoid arthritis-
dc.subjectstructure activity relation-
dc.subjectstructure analysis-
dc.subjecttuberculosis-
dc.subjectulcerative colitis-
dc.subjectAnimals-
dc.subjectAntibodies-
dc.subjectDrug Carriers-
dc.subjectDrug Delivery Systems-
dc.subjectDrug Design-
dc.subjectGene Therapy-
dc.subjectHumans-
dc.subjectLectins-
dc.subjectMacromolecular Substances-
dc.subjectOsteoporosis-
dc.subjectProdrugs-
dc.subjectViruses-
dc.titleAdvances in prodrug designen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.description.affiliationLaboratório de Pesquisa e Desenvolvimento de Fármacos Departamento de Fármacos e Medicamentos UNESP, Araraquara-
dc.description.affiliationLaboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos Departamento de Farmácia USP/SP, São Paolo-
dc.description.affiliationUnespLaboratório de Pesquisa e Desenvolvimento de Fármacos Departamento de Fármacos e Medicamentos UNESP, Araraquara-
dc.identifier.doi10.2174/138955705774329528-
dc.identifier.wosWOS:000231837000003-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofMini-Reviews in Medicinal Chemistry-
dc.identifier.scopus2-s2.0-24944549193-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
Show simple item record Show full item record   View Statistics
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.